Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • Bafilomycin A1: Precision V-ATPase Inhibitor for Lysosoma...

    2026-02-15

    Bafilomycin A1: Precision V-ATPase Inhibitor for Lysosomal and pH Research

    Executive Summary: Bafilomycin A1 is a potent, selective, and reversible inhibitor of vacuolar-type H+-ATPases (V-ATPases), with complete inhibition of proton transport at concentrations as low as 10 nM in vitro (Yoshimori 1991, DOI). The compound is widely used in cell biology for dissecting intracellular pH regulation, lysosomal acidification, and osteoclast-mediated bone resorption (Bowman 1988, DOI). Bafilomycin A1, supplied by APExBIO, features an IC50 range of 4–400 nM depending on the V-ATPase source organism and cell model (product page). It is a crystalline solid, soluble in DMSO at >10 mM, and should be stored desiccated at -20°C for optimal stability. The compound is a key tool in mechanistic studies of autophagy, mitophagy, and caspase-dependent signaling, as summarized in recent primary literature (DOI).

    Biological Rationale

    Bafilomycin A1 targets V-ATPases, which are multisubunit enzymes mediating proton translocation across intracellular organelle membranes. V-ATPases are essential for maintaining acidic pH in lysosomes, endosomes, and secretory vesicles (Forgac 2007, DOI). Inhibition of these pumps disrupts acidification, which is critical for lysosomal enzyme activity, vesicular trafficking, and nutrient processing. In osteoclasts, V-ATPase function underpins bone resorption by acidifying the resorption lacuna. Dysregulation of V-ATPase activity is implicated in cancer, neurodegenerative diseases, and infectious processes (Saftig 2016, DOI). Thus, selective inhibitors like Bafilomycin A1 are central to probing these pathways and modeling disease mechanisms.

    Mechanism of Action of Bafilomycin A1

    Bafilomycin A1 binds to the V0 sector of the V-ATPase complex, directly blocking proton translocation (Bowman 1988, DOI). This action is reversible and highly selective, distinguishing Bafilomycin A1 from broad-spectrum protonophores. At 10 nM, it completely inhibits proton movement in isolated lysosomal vesicles. The compound's IC50 varies with source: 4 nM in bovine chromaffin granules, up to 400 nM in yeast vacuoles (Yoshimori 1991, DOI). Bafilomycin A1 does not disrupt plasma membrane Na+/K+-ATPases at experimental concentrations, ensuring target selectivity. In cell models, Bafilomycin A1 blocks vacuolization and can restore normal morphology to HeLa cells challenged with Helicobacter pylori toxin at 12.5 nM (APExBIO).

    Evidence & Benchmarks

    • Bafilomycin A1 inhibits V-ATPase activity with an IC50 of 4–400 nM, depending on the organism and vesicle type (Bowman 1988, DOI).
    • Complete block of lysosomal proton transport occurs at 10 nM in vitro (Yoshimori 1991, DOI).
    • In HeLa cells, Bafilomycin A1 reverses Helicobacter pylori-induced vacuolization at 12.5 nM, with a 50% effect at 4 nM (APExBIO).
    • In freshwater tilapias, Bafilomycin A1 inhibits Na+ uptake with a Ki of 1.6 × 10⁻⁷ mol/L (Lin 2006, DOI).
    • Bafilomycin A1 is stable as a crystalline solid but solutions should not be stored long-term; stock solutions in DMSO are stable below -20°C for several months (APExBIO).
    • Bafilomycin A1 is widely used to dissect the role of V-ATPase in autophagy, lysosomal function, and caspase signaling pathways in cancer and neurodegenerative disease models (Delgado et al. 2022, DOI).

    Applications, Limits & Misconceptions

    Bafilomycin A1 is a critical reagent for:

    • Studying intracellular pH regulation and lysosomal acidification (Vatalis.info article). This article expands by detailing quantitative benchmarks and mechanism-of-action, providing specific conditions for maximal inhibition.
    • Blocking osteoclast-mediated bone resorption by inhibiting proton pumps at the ruffled border.
    • Modeling the impact of lysosomal pH on autophagy and assessing autophagic flux (Octocrylenechem article). Our discussion complements this scenario-driven piece by presenting cross-species benchmarks and storage parameters.
    • Dissecting caspase-dependent and caspase-independent cell death pathways during mitotic and interphase events (Delgado et al. 2022, DOI).

    Common Pitfalls or Misconceptions

    • Bafilomycin A1 is not a general ATPase inhibitor; it is selective for V-ATPase and does not affect plasma membrane Na+/K+-ATPase at standard concentrations.
    • It does not directly induce apoptosis; rather, it modulates lysosomal and autophagic pathways that may influence cell death under specific conditions.
    • Long-term storage of Bafilomycin A1 in solution leads to significant loss of potency; always prepare fresh or use frozen aliquots (APExBIO).
    • Bafilomycin A1 should not be used to probe mitochondrial ATP synthase inhibition; it lacks cross-reactivity for mitochondrial F-type ATPases.
    • Observed effects in cancer or neurodegeneration models may reflect global changes in lysosomal pH, not just V-ATPase inhibition.

    Workflow Integration & Parameters

    Bafilomycin A1 (SKU: A8627) from APExBIO is supplied as a crystalline solid. It is soluble in DMSO at concentrations over 10 mM. For cell culture, dilute stock solutions to final working concentrations (typically 4–100 nM) in pre-warmed culture media. Solutions should be used promptly after thawing. For long-term storage, aliquot DMSO stocks and keep at -20°C in a desiccated environment. Shipping is on Blue Ice for stability. Bafilomycin A1 is compatible with fluorescence-based pH assays, lysosomal activity probes, and autophagic flux markers. For advanced integration guidance, see our contrast with Vatalis.com’s expert workflow guide, which Bafilomycin A1 usage here updates with the latest caspase pathway benchmarks.

    Conclusion & Outlook

    Bafilomycin A1 is the gold-standard selective V-ATPase inhibitor for dissecting lysosomal function, intracellular pH regulation, and autophagic flux. Its potency, specificity, and reversibility position it as an essential tool in cell biology, cancer, and neurodegenerative disease research. Recent studies using APExBIO’s Bafilomycin A1 provide robust, reproducible results across model systems. Ongoing advances in disease modeling and signaling pathway interrogation continue to affirm its value in experimental design. For ordering details and technical specifications, visit the Bafilomycin A1 product page.